TY - JOUR
T1 - Genetic variation at 16q24.2 is associated with small vessel stroke
AU - on behalf of the International Stroke Genetics Consortium
AU - METASTROKE, UK Young Lacunar DNA Study, NINDS Stroke Genetics Network, Neurology Working Group of the CHARGE Consortium
AU - Traylor, Matthew
AU - Malik, Rainer
AU - Nalls, Mike A.
AU - Cotlarciuc, Ioana
AU - Radmanesh, Farid
AU - Thorleifsson, Gudmar
AU - Hanscombe, Ken B.
AU - Langefeld, Carl
AU - Saleheen, Danish
AU - Rost, Natalia S.
AU - Yet, Idil
AU - Spector, Tim D.
AU - Bell, Jordana T.
AU - Hannon, Eilis
AU - Mill, Jonathan
AU - Chauhan, Ganesh
AU - Debette, Stephanie
AU - Bis, Joshua C.
AU - Longstreth, W. T.
AU - Ikram, M. Arfan
AU - Launer, Lenore J.
AU - Seshadri, Sudha
AU - Hamilton-Bruce, Monica Anne
AU - Jimenez-Conde, Jordi
AU - Cole, John W.
AU - Schmidt, Reinhold
AU - Słowik, Agnieszka
AU - Lemmens, Robin
AU - Lindgren, Arne
AU - Melander, Olle
AU - Grewal, Raji P.
AU - Sacco, Ralph L.
AU - Rundek, Tatjana
AU - Rexrode, Kathryn
AU - Arnett, Donna K.
AU - Johnson, Julie A.
AU - Benavente, Oscar R.
AU - Wasssertheil-Smoller, Sylvia
AU - Lee, Jin Moo
AU - Pulit, Sara L.
AU - Wong, Quenna
AU - Rich, Stephen S.
AU - de Bakker, Paul I.W.
AU - McArdle, Patrick F.
AU - Woo, Daniel
AU - Anderson, Christopher D.
AU - Xu, Huichun
AU - Heitsch, Laura
AU - Fornage, Myriam
AU - Meschia, James F.
N1 - Funding Information:
Matthew Traylor is funded by the NIHR Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London. Hugh Markus is supported by an NIHR Senior Investigator award and his work is supported by NIHR Comprehensive Biomedical Research Unit funding awarded to Cambridge University Hospitals Trust. Cathryn Lewis receives salary support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Collection of the UK Young Lacunar Stroke DNA Study (DNA Lacunar) was primarily supported by the Wellcome Trust (WT072952) with additional support from the Stroke Association (TSA 2010/01). Genotyping of the DNA Lacunar samples was supported by a Stroke Association Grant (TSA 2013/01). Robin Lemmens is a senior clinical investigator of FWO Flanders. Martin Dichgans received funding from the DFG (CRC 1123, B3) and an EU Horizon 2020 grant (agreement No. 666881 SVDs@target). The TwinsUK study was funded, in part, by the European Research Council (ERC 250157), and from the TwinsUK resource, which receives support from the Wellcome Trust and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust in partnership with King's College London. SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute through NIH/CIDR. The SiGN study was funded by a cooperative agreement grant from the US National Institute of Neurological Disorders and Stroke, National Institutes of Health (U01 NS069208).
Publisher Copyright:
© 2016 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Objective: Genome-wide association studies (GWAS) have been successful at identifying associations with stroke and stroke subtypes, but have not yet identified any associations solely with small vessel stroke (SVS). SVS comprises one quarter of all ischemic stroke and is a major manifestation of cerebral small vessel disease, the primary cause of vascular cognitive impairment. Studies across neurological traits have shown that younger-onset cases have an increased genetic burden. We leveraged this increased genetic burden by performing an age-at-onset informed GWAS meta-analysis, including a large younger-onset SVS population, to identify novel associations with stroke. Methods: We used a three-stage age-at-onset informed GWAS to identify novel genetic variants associated with stroke. On identifying a novel locus associated with SVS, we assessed its influence on other small vessel disease phenotypes, as well as on messenger RNA (mRNA) expression of nearby genes, and on DNA methylation of nearby CpG sites in whole blood and in the fetal brain. Results: We identified an association with SVS in 4,203 cases and 50,728 controls on chromosome 16q24.2 (odds ratio [OR; 95% confidence interval {CI}] = 1.16 [1.10–1.22]; p = 3.2 × 10−9). The lead single-nucleotide polymorphism (rs12445022) was also associated with cerebral white matter hyperintensities (OR [95% CI] = 1.10 [1.05–1.16]; p = 5.3 × 10−5; N = 3,670), but not intracerebral hemorrhage (OR [95% CI] = 0.97 [0.84–1.12]; p = 0.71; 1,545 cases, 1,481 controls). rs12445022 is associated with mRNA expression of ZCCHC14 in arterial tissues (p = 9.4 × 10−7) and DNA methylation at probe cg16596957 in whole blood (p = 5.3 × 10−6). Interpretation: 16q24.2 is associated with SVS. Associations of the locus with expression of ZCCHC14 and DNA methylation suggest the locus acts through changes to regulatory elements. Ann Neurol 2017;81:383–394.
AB - Objective: Genome-wide association studies (GWAS) have been successful at identifying associations with stroke and stroke subtypes, but have not yet identified any associations solely with small vessel stroke (SVS). SVS comprises one quarter of all ischemic stroke and is a major manifestation of cerebral small vessel disease, the primary cause of vascular cognitive impairment. Studies across neurological traits have shown that younger-onset cases have an increased genetic burden. We leveraged this increased genetic burden by performing an age-at-onset informed GWAS meta-analysis, including a large younger-onset SVS population, to identify novel associations with stroke. Methods: We used a three-stage age-at-onset informed GWAS to identify novel genetic variants associated with stroke. On identifying a novel locus associated with SVS, we assessed its influence on other small vessel disease phenotypes, as well as on messenger RNA (mRNA) expression of nearby genes, and on DNA methylation of nearby CpG sites in whole blood and in the fetal brain. Results: We identified an association with SVS in 4,203 cases and 50,728 controls on chromosome 16q24.2 (odds ratio [OR; 95% confidence interval {CI}] = 1.16 [1.10–1.22]; p = 3.2 × 10−9). The lead single-nucleotide polymorphism (rs12445022) was also associated with cerebral white matter hyperintensities (OR [95% CI] = 1.10 [1.05–1.16]; p = 5.3 × 10−5; N = 3,670), but not intracerebral hemorrhage (OR [95% CI] = 0.97 [0.84–1.12]; p = 0.71; 1,545 cases, 1,481 controls). rs12445022 is associated with mRNA expression of ZCCHC14 in arterial tissues (p = 9.4 × 10−7) and DNA methylation at probe cg16596957 in whole blood (p = 5.3 × 10−6). Interpretation: 16q24.2 is associated with SVS. Associations of the locus with expression of ZCCHC14 and DNA methylation suggest the locus acts through changes to regulatory elements. Ann Neurol 2017;81:383–394.
UR - http://www.scopus.com/inward/record.url?scp=85016118346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016118346&partnerID=8YFLogxK
U2 - 10.1002/ana.24840
DO - 10.1002/ana.24840
M3 - Article
C2 - 27997041
AN - SCOPUS:85016118346
SN - 0364-5134
VL - 81
SP - 383
EP - 394
JO - Annals of neurology
JF - Annals of neurology
IS - 3
ER -